Read twice and referred to the Committee on Finance.
The Competitive Bidding Relief Act directs the HHS Secretary to apply the transition rule at 42 C.F.R. §414.210(g)(9)(v) to durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) items that were included in Round 2021 of the competitive bidding program for all areas except rural and noncontiguous areas through December 31, 2025. It also delays implementation of the subsequent regulatory step at 42 C.F.R. §414.210(g)(9)(vi) until January 1, 2026.
Fiscal impact vs. access: liberals and centrists demand evidence of fiscal cost and beneficiary access data; conservatives emphasize avoiding supplier disruption even if it risks short-term higher spending.
Relative to its intended legislative type, this bill is a narrowly targeted administrative directive that clearly identifies the agency actor, specific regulatory provisions, and precise dates for applying or delaying those provisions.
The Competitive Bidding Relief Act directs the HHS Secretary to apply the transition rule at 42 C.F.R. §414.210(g)(9)(v) to durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) items that were included in Round 2021 of the competitive bidding program for all areas except rural and noncontiguous areas through December 31, 2025.
It also delays implementation of the subsequent regulatory step at 42 C.F.R. §414.210(g)(9)(vi) until January 1, 2026.
The bill allows the Secretary to enact these changes by program instruction or other administrative action.
Content-alone, this is a narrowly tailored, administratively implementable adjustment to a Medicare payment rule with limited ideological salience and a built-in sunset, which historically improves chances. However, potential near-term fiscal cost (unknown magnitude), competing legislative priorities, and the fact that administrators can sometimes effect similar relief without new statute reduce the chance it must become law. Its passage is plausible if packaged with other Medicare/provider measures or noncontroversial must-pass legislation, but unlikely as a high-profile standalone priority.
Relative to its intended legislative type, this bill is a narrowly targeted administrative directive that clearly identifies the agency actor, specific regulatory provisions, and precise dates for applying or delaying those provisions. It is specific about the regulatory text to be invoked and allows flexible implementation by program instruction.
Fiscal impact vs. access: liberals and centrists demand evidence of fiscal cost and beneficiary access data; conservatives emphasize avoiding supplier disruption even if it risks short-term higher spending.
These are examples from the analysis, not a ranked list of the most-affected groups.
Fiscal impact vs. access: liberals and centrists demand evidence of fiscal cost and beneficiary access data; conservatives emphasize avoiding supplier disruption even if it risks short-term higher spending.
A liberal/left-leaning observer would view the bill as a short-term relief measure that may protect patients’ access to needed medical equipment and small community suppliers from sudden payment reductions.
They would be cautious because the competitive bidding program was designed to lower Medicare spending and reduce overpayments; delaying parts of it could increase costs.
They would want transparency, data on access impacts, and limits to ensure this temporary relief does not permanently erode cost controls or harm equity.
A centrist/moderate would treat the bill as a pragmatic, narrow pause to avoid immediate market disruption while giving administrators time to implement regulatory changes carefully.
They would like concrete cost estimates and performance metrics to justify the delay and ensure it remains temporary.
If the measure is strictly time-limited and accompanied by reporting requirements, a centrist is likely to support it as a balanced administrative fix.
A mainstream conservative would likely welcome this bill as a modest, targeted intervention that prevents abrupt payment cuts that could force DME suppliers out of the market and reduce beneficiary access.
They would view the temporary delay as sensible relief for small businesses and patients while preserving the overall framework of competitive bidding.
However, they would prefer the relief to remain temporary, fiscally responsible, and not expand federal micromanagement beyond what is needed to protect access.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-alone, this is a narrowly tailored, administratively implementable adjustment to a Medicare payment rule with limited ideological salience and a built-in sunset, which historically improves chances. However, potential near-term fiscal cost (unknown magnitude), competing legislative priorities, and the fact that administrators can sometimes effect similar relief without new statute reduce the chance it must become law. Its passage is plausible if packaged with other Medicare/provider measures or noncontroversial must-pass legislation, but unlikely as a high-profile standalone priority.
The bill has not accumulated any surfaced votes yet.
Fiscal impact vs. access: liberals and centrists demand evidence of fiscal cost and beneficiary access data; conservatives emphasize avoidi…
Content-alone, this is a narrowly tailored, administratively implementable adjustment to a Medicare payment rule with limited ideological s…
Relative to its intended legislative type, this bill is a narrowly targeted administrative directive that clearly identifies the agency actor, specific regulatory provisions, and precise dates for applying or delaying t…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.